Although some ICIs (such as anti-PD-1 antibodies and anti-CTLA-4 antibodies) have been approved for first-line or second-line treatment of HCC in some countries, some advanced HCC patients do not respond to therapy, and the overall response rate remains low (93). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.